Background
==========

The successful treatment of colorectal cancer (CRC) relies on an early diagnosis, radical surgery and adequate adjuvant treatment. Presently, tumour stage at diagnosis is the most important prognostic factor. However, it is becoming increasingly clear that CRC is a highly heterogeneous disease with different genetic and molecular characteristics affecting intrinsic tumour aggressiveness, response to systemic treatment, and, hence, clinical outcome. Although many efforts have been made to find biomarkers to more accurately predict high-risk disease and to select patients for adjuvant treatment, none have proven good enough for use in clinical routine.

Activating mutations of proto-oncogenes KRAS and BRAF are common in CRC, causing unregulated downstream signalling in the Ras/Raf/MEK/MAP signal transduction pathway, in turn, affecting a variety of cellular responses such as proliferation, differentiation, migration, survival and apoptosis \[[@B1]\]. Approximately 40% of all colorectal tumours harbour a KRAS mutation, predominantly occurring in codon 12 or 13 \[[@B2]\]. While KRAS mutation has proven to be predictive of the resistance to epidermal growth factor receptor (EGFR)-inhibiting therapies \[[@B3],[@B4]\], the prognostic value of KRAS mutation in CRC remains unclear. Numerous studies have investigated the relationship between KRAS mutation status and survival from CRC with divergent results; however, the majority of them are associating KRAS mutation with a poor prognosis \[[@B5]-[@B11]\]. Notably, while most studies did not consider specific mutations, accumulating evidence indicates that specific codon 12 and 13 mutations have a stronger impact on the functionality of the KRAS protein, and, hence, its impact on clinical outcome in CRC patients \[[@B5],[@B12],[@B13]\].

BRAF mutations have been reported in CRC at a frequency of 5%--18% with the vast majority being a V600E substitution \[[@B14]\]. BRAF mutation has also been linked to an impaired prognosis in CRC \[[@B9],[@B15],[@B16]\] and unresponsiveness to anti-EGFR drugs \[[@B17]-[@B19]\]. BRAF and KRAS mutations are, with rare exceptions, mutually exclusive \[[@B20]\].

The prognostic value of clinicopathological factors \[[@B21],[@B22]\] and investigative biomarkers \[[@B23]\] may well differ in men and women, but to our best knowledge, no previous studies have investigated sex-related differences in the prognostic impact of KRAS and BRAF mutation in CRC. In the present study, we examined the associations of specific KRAS and BRAF mutations with clinicopathological and tumour biological characteristics, and survival, in 525 incident cases of colorectal cancer from a prospective population-based cohort study.

Methods
=======

Study population
----------------

Until the end of follow-up in 31 December 2008, 626 incident cases of CRC had been registered in the prospective population-based cohort from the Malmö Diet and Cancer Study (MDCS) \[[@B22],[@B24]\]. Patient and tumour characteristics of the cohort have been described in detail previously \[[@B23],[@B25]-[@B27]\]. Ethical permission was obtained from the Ethics Committee at Lund University. Tissue microarrays have been constructed from 557 cases as previously described \[[@B23],[@B25]\]. Immunohistochemical analysis of mismatch repair proteins MLH1, PMS2, MSH2 and MSH6 for the assessment of microsatellite instability (MSI) status has been described in \[[@B26]\], analysis of beta-catenin overexpression in \[[@B27]\], of cyclin D1 in \[[@B23]\], and p21, p27 and p53 in \[[@B28]\].

Analysis of KRAS and BRAF mutation status
-----------------------------------------

The PyroMark Q24 system (Qiagen GmbH, Hilden, Germany) was used for pyrosequencing analysis of KRAS and BRAF mutations in DNA from 1 mm formalin-fixed, paraffin-embedded tumour tissue cores taken from areas with \>90% tumour cells. In brief, genomic DNA was extracted from tumour tissue using QIAamp MinElute spin columns (Qiagen) and DNA regions of interest were PCR-amplified (Veriti 96-Well Fast Thermal Cycler, Applied Biosystems Inc., Foster City, CA, USA). KRAS codons 12 and 13 were analysed using Therascreen KRAS Pyro Kit (Qiagen). Analysis of BRAF mutation hotspots in codons 600 and 601 was performed using previously published PCR primers \[[@B29]\] and a novel BRAF sequencing primer (5′-TGATTTTGGTCTAGCTACA-3′) which was designed using the PyroMark Assay Design 2.0 software (Qiagen). All samples with a potential low-level mutation were reanalysed.

Statistical analysis
--------------------

Associations between KRAS and BRAF mutation status and clinicopathological factors were explored by Pearson\'s Chi-square test. Kaplan-Meier analysis and log rank test were performed to illustrate the differences in cancer-specific survival (CSS). Cox proportional hazards regression was used for estimation of hazard ratio (HR) for death from CRC. A backward conditional method was used for variable selection in the multivariable model including age, gender, T stage, N stage, M stage, differentiation grade, vascular invasion, MSI status, and KRAS and BRAF mutation status. The interaction between investigative factors and sex was explored by a Cox model including the interaction variable. All survival analyses were repeated with overall mortality as endpoint and all tests were two-sided. A *p* value of 0.05 was considered significant. All statistical analyses were performed using IBM SPSS Statistics version 20.0.

Results
=======

Distribution of KRAS and BRAF mutations
---------------------------------------

KRAS and BRAF mutations were successfully evaluated in 525 and 524 cases, respectively. The distribution of specific KRAS mutations is shown in Table [1](#T1){ref-type="table"}. A total number of 334 (63.7%) tumours were KRAS wild-type and 191 (36.4%) were KRAS-mutated. Specifically, 156 (29.8%) cases harboured a KRAS codon 12 mutation, 34 (6.5%) a KRAS codon 13 mutation and 1 case (0.2%) had dual codons 12 and 13 mutations. The distribution of specific KRAS mutations did not differ between sexes (data not shown). KRAS and BRAF mutations were mutually exclusive. Further, 446 (85.1%) of the tumours were BRAF wild-type, 76 (14.5%) were BRAF V600E-mutated and 2 (0.4%) were BRAF K601E-mutated with a total of 78 (14.9%) cases harbouring a BRAF mutation.

###### 

Distribution of KRAS mutations in 191 cases

   **Codon**   **Sequence (amino acid)**   **Number (%)**
  ----------- --------------------------- ----------------
      12               CGT (Arg)              2 (1.0)
   GAT (Asp)           57 (29.8)          
   GTT (Val)           60 (31.4)          
   TGT (Cys)           15 (7.9)           
   AGT (Ser)           13 (6.8)           
   GCT (Ala)           10 (5.2)           
      13               GAC (Asp)             33 (17.3)
                       GTC (Val)              1 (0.5)

Correlations of KRAS and BRAF mutations with clinicopathological and tumour biological parameters
-------------------------------------------------------------------------------------------------

As shown in Table [2](#T2){ref-type="table"}, there was a significant association between KRAS wild-type tumours and MSI. Further, KRAS codon 13 mutation correlated with metastatic disease (M1) and p27 negativity. Notably, when KRAS codon 12-mutated tumours were compared with tumours being either KRAS wild-type or codon 13-mutated, there was a significantly higher proportion of mucinous tumours in the former category (*p* = 0.032 and *p* = 0.024).

###### 

Associations of KRAS codons 12 and 13, and BRAF mutation status with clinicopathological and molecular characteristics

                           **KRAS wild-type**   **Codon 12-mutated**   **Codon 13-mutated**   ***p*value**   **BRAF wild-type**   **BRAF-mutated**   ***p*value**
  ----------------------- -------------------- ---------------------- ---------------------- -------------- -------------------- ------------------ --------------
  Age                                                                                                                                                      
   Mean, median                70.5, 71.4            70.9, 71.4             68.5, 69.6          0.297^b^         70.2, 70.8          72.0, 73.1        0.017^b^
   Range                       51.5--85.6            50.9--84.0             49.8--83.7         49.8--86.6        51.5--84.3                         
  Sex                                                                                                                                                      
   Female                      177 (53.0)            83 (53.2)              18 (52.9)            0.999           227 (50.9)          50 (64.1)          0.031
   Male                        157 (47.0)            73 (46.8)              16 (47.1)          219 (49.1)        28 (35.9)                          
  Tumour location                                                                                                                                          
   Proximal                    101 (30.4)            54 (34.6)              10 (29.4)            0.058           106 (23.8)          59 (77.6)         \<0.001
   Transverse                   18 (5.4)               0 (0)                 3 (8.8)            11 (2.5)         10 (13.2)                          
   Descending                   15 (4.5)              12 (7.7)               1 (2.9)            24 (5.4)          4 (5.3)                           
   Sigmoid                     66 (19.9)             38 (24.4)               7 (20.6)          110 (24.7)         1 (1.3)                           
   Rectum                      132 (39.8)            52 (33.3)              13 (38.2)          195 (43.7)         2 (2.6)                           
   Missing                         2                     \-                     \-                 0                 2                              
  T stage                                                                                                                                                  
   1                           32 (10.0)              9 (6.0)                4 (13.3)            0.291            42 (9.9)            3 (4.1)           0.001
   2                           38 (11.9)             18 (11.9)               2 (6.7)           52 (12.2)          6 (8.1)                           
   3                           201 (63.0)            104 (68.9)             16 (53.3)          278 (65.3)        43 (58.1)                          
   4                           48 (15.0)             20 (13.2)               8 (26.7)          54 (12.7)         22 (29.7)                          
   Missing                         15                    5                      4                  20                4                              
  N stage                                                                                                                                                  
   0                           180 (59.6)            84 (57.9)              15 (51.7)            0.710           241 (59.7)          37 (51.4)          0.353
   1                           69 (22.8)             39 (26.9)               7 (24.1)          97 (24.0)         19 (26.4)                          
   2                           53 (17.5)             22 (15.2)               7 (24.1)          66 (16.3)         16 (22.2)                          
   Missing                         32                    12                     5                  42                6                              
  M stage                                                                                                                                                  
   0                           275 (84.1)            128 (82.6)             22 (64.7)            0.018           366 (83.0)          59 (78.7)          0.363
   1                           52 (15.9)             27 (17.4)              12 (35.3)          75 (17.0)         16 (21.3)                          
   Missing                         17                    1                      \-                 5                 3                              
  Differentiation grade                                                                                                                                    
   High                         20 (6.2)              11 (7.1)                0 (0)              0.088            25 (5.7)            5 (6.8)          \<0.001
   Intermediate                222 (68.7)            121 (77.6)             26 (76.5)          340 (77.4)        30 (40.5)                          
   Low                         81 (25.1)             24 (15.4)               8 (23.5)          74 (16.9)         39 (52.7)                          
   Missing                         11                    \-                     \-                 7                 4                              
  Vascular invasion                                                                                                                                        
   No                          95 (51.1)             45 (47.4)              7 ( 38.9)            0.561           125 (49.4)          21 (46.7)          0.735
   Yes                         91 (48.9)             50 (52.6)              11 (61.1)          128 (50.6)        24 (53.3)                          
   Missing                        148                    61                     16                193                33                             
  Tumour type                                                                                                                                              
   Non-mucinous                269 (82.0)            114 (73.5)             28 (84.8)            0.073           360 (81.8)          50 (65.8)          0.001
   Mucinous                    59 (18.0)             41 (26.5)               5 (15.2)          80 (18.2)         26 (34.2)                          
   Missing                         6                     1                      1                  6                 2                              
  MSI screening status                                                                                                                                     
   MSS                         245 (79.3)            137 (96.5)             31 (93.9)           \<0.001          384 (93.2)          29 (40.3)         \<0.001
   MSI                         64 (20.7)              5 (3.5)                2 (6.1)            28 (6.8)         43 (59.7)                          
   Missing                         25                    14                     1                  24                6                              
  Beta-catenin grades                                                                                                                                      
   0--1                        94 (29.7)             37 (25.0)              13 (38.2)            0.470           99 (23.4)           45 (59.2)         \<0.001
   2--3                        108 (34.1)            48 (32.4)               9 (26.5)          138 (32.6)        26 (34.2)                          
   4--5                        115 (36.3)            63 (42.6)              12 (35.3)          186 (44.0)         5 (6.6)                           
   Missing                         17                    8                      \-                 23                2                              
  p53 status                                                                                                                                               
   Negative                    169 (53.1)            77 (51.3)              12 (37.5)            0.240           202 (47.6)          57 (75.0)         \<0.001
   Positive                    149 (46.9)            73 (48.7)              20 (62.5)          222 (52.4)        19 (25.0)                          
   Missing                         16                    6                      2                  22                2                              
  p21 Expression                                                                                                                                           
   Negative                    43 (13.7)             22 (14.9)               5 (15.2)            0.931           63 (15.0)            7 (9.2)           0.180
   Positive                    271 (86.3)            126 (85.1)             28 (84.8)          356 (85.0)        69 (90.8)                          
   Missing                         20                    8                      1                  27                2                              
  p27 Expression                                                                                                                                           
   Negative                    58 (18.4)             15 (10.1)               9 (27.3)            0.018           51 (12.1)           31 (40.8)         \<0 001
   Positive                    258 (81.6)            134 (89.9)             24 (72.7)          371 (87.9)        45 (59.2)                          
   Missing                         18                    7                      1                  24                2                              
  Cyclin D1 expression                                                                                                                                     
   Negative                    63 (20.0)             23 (15.4)              10 (30.3)            0.129           90 (21.4)            5 (6.6)           0.003
   Positive                    252 (80.0)            126 (84.6)             23 (69.7)          331 (78.6)        71 (93.4)                          
   Missing                         19                    7                      1                                    25                  2                 

^a^*n* (%); ^b^Kruskal-Wallis or Mann--Whitney U test. *MSI* microsatellite unstable, *MSS* microsatellite stable. One case with mutual codons 12 and 13 mutation was excluded from the analyses related to KRAS mutational status.

BRAF mutation was significantly associated with older age, female sex, proximal tumour location, low differentiation grade, mucinous tumour type, MSI and expression of cyclin D1, and inversely associated with beta-catenin overexpression, p53 positivity and p27 expression.

Prognostic significance of KRAS and BRAF mutations
--------------------------------------------------

Hazard ratios for CSS according to KRAS and BRAF mutation status in the entire cohort, and strata according to sex, are shown in Table [3](#T3){ref-type="table"}. In the entire cohort, a similar survival was seen for patients with KRAS wild-type and codon 12-mutated tumours, while patients with tumours harbouring a KRAS codon 13 mutation had a significantly reduced CSS (HR = 1.94; 95% CI = 1.18--3.19) in unadjusted, but not in adjusted analysis. KRAS codon 13, but not codon 12, mutation was also significantly associated with poor prognosis in women (HR = 2.58; 95% CI = 1.31--5.09) in unadjusted, but not in adjusted analysis. The KRAS mutation status was not prognostic in men.

###### 

Risk of death from colorectal cancer according to KRAS codons 12 and 13, and BRAF mutations

                              **Entire cohort**                   **Women**                        **Men**        
  -------------------------- ------------------- ----------- -------------------- ---------- ------------------- ----------
  KRAS status (unadjusted)                                                                                        
   Wild-type                        1.00         334 (113)           1.00         177 (52)          1.00         157 (61)
   Codon 12-mutated           1.05 (0.76--1.45)  156 (54)     1.32 (0.85--2.05)   83 (32)     0.81 (0.50--1.32)  73 (22)
   Codon 13-mutated           1.94 (1.18--3.19)  34 (18)      2.58 (1.31--5.09)   18 (10)     1.42 (0.68--2.96)  16 (8)
  KRAS status (adjusted)                                                                                          
   Wild-type                        1.00         273 (87)            1.00         146 (39)          1.00         127 (65)
   Codon 12-mutated           1.02 (0.69--1.51)  132 (44)     1.29 (0.75--2.22)   67 (24)     0.74 (0.42--1.30)  65 (20)
   Codon 13-mutated           1.37 (0.74--2.54)  28 (13)      1.83 (0.79--4.23)   15 (7)      0.87 (0.34--2.72)  13 (6)
  BRAF status (unadjusted)                                                                                        
   Wild-type                        1.00         446 (154)           1.00         227 (75)          1.00         219 (79)
   Mutated                    1.32 (0.90--1.94)  78 (32)      1.23 (0.74--2.04)   50 (19)     1.56 (0.87--2.81)  28 (13)
  BRAF status (adjusted)                                                                                          
   Wild-type                        1.00         370 (122)           1.00         184 (56)          1.00         186 (66)
   Mutated                    1.56 (0.87--2.79)  63 (22)      1.47 ( 0.65--3.33)  44 (14)     3.50 (1.41--8.70)  19 (8)

Adjusted analysis included age (continuous), sex, T stage (I-II, III, IV), N stage (0, 1, 2), M stage (0, 1), differentiation grade (high-intermediate vs. low and vascular invasion (+/−/unknown)), KRAS mutation status (wild-type, codon 12 mutation, codon 13 mutation) and BRAF mutation status (wild-type, mutated). One case with mutual KRAS codons 12 and 13 mutation was excluded from the analyses related to KRAS mutational status.

There were no significant associations of BRAF mutation with CSS in the entire cohort or in women, neither in unadjusted nor in adjusted analysis. In men, BRAF mutation was not prognostic in unadjusted, but in adjusted analysis (HR = 3.50; 95% CI = 1.41--8.70). This finding led us to investigate whether the prognostic value of BRAF differs in different disease stages in men and women and found that BRAF status was particularly prognostic in lymph node-positive disease in men, but not in women (data not shown).

Specific point mutations in KRAS codon 12 or 13 had no significant impact on survival, neither in the entire cohort nor in strata according to gender (data not shown). Similar results were observed for the overall survival (data not shown). KRAS and BRAF mutation status did not predict response to standard adjuvant chemotherapy in curatively treated patients with stages III and IV disease (data not shown).

Prognostic value of BRAF mutation according to MSI status
---------------------------------------------------------

As BRAF mutation has been previously reported to be associated with a particularly poor survival in cases with microsatellite stable (MSS) tumours \[[@B8],[@B15],[@B30],[@B31]\], we also examined whether the prognostic value of BRAF mutation differs by MSI status, overall and stratified for sex. As shown in Table [4](#T4){ref-type="table"}, BRAF mutation was overall associated with a significantly shorter CSS in patients with MSS tumours in unadjusted analysis (HR = 2.36; 95% CI = 1.44--3.86) and borderline significant in adjusted analysis (HR = 1.80; 95% CI = 0.98--3.28). BRAF mutation was not prognostic in MSI tumours. Again, no prognostic significance was found for BRAF mutation in women, either in MSS or in MSI tumours. In men, BRAF mutation was an independent factor of poor prognosis in MSS tumours (unadjusted HR = 3.46, 95% CI = 1.78--6.74; adjusted HR = 4.91, 95% CI = 1.99--12.12). Adjusted analysis was not performed in MSI tumours due to the small subgroups.

###### 

Risk of death from colorectal cancer according to BRAF mutation and by microsatellite instability status

                                          **Entire cohort**                    **Women**                        **Men**         
  -------------------------------------- -------------------- ----------- -------------------- ---------- -------------------- ----------
  BRAF status-MSS tumours (unadjusted)                                                                                          
   Wild-type                                     1.00         384 (135)           1.00         194 (64)           1.00         190 (71)
   Mutated                                2.36 (1.44--3.86)   29 (18)      1.73 (0.83--3.61)   16 (8)      3.46 (1.78--6.74)   13 (10)
  BRAF status-MSI tumours (unadjusted)                                                                                          
   Wild-type                                     1.00         28 (4)              1.00         16 (2)             1.00         12 (2)
   Mutated                                1.68 (0.53--5.36)   43 (10)      2.15 (0.46--10.12)  31 (8)      1.03 (0.14--7.31)   12 (2)
  BRAF status-MSS tumours (adjusted)                                                                                            
   Wild-type                                     1.00         343 (118)           1.00         169 (54)           1.00         174 (64)
   Mutated                                1.80 (0.98--3.28)   23 (14)      1.37 (0.56--3.35)   14 (7)      4.91 (1.99--12.12)  9 (7)
  BRAF status-MSI tumours (adjusted)                                                                                            
   Wild-type                                     1.00         27 (4)               \-          \-                  \-          \-
   Mutated                                3.24 (0.39--26.92)  40 (8)               \-          \-                  \-          \-

Adjusted analysis included age (continuous), sex, T stage (I-II, III, IV), N stage (0,1,2), M stage (0, 1), differentiation grade (high-intermediate vs. low and vascular invasion (+/−/unknown)) and KRAS mutation status (wild-type, codon 12 mutation, codon 13 mutation). One case with mutual KRAS codons 12 and 13 mutation was excluded from the adjusted analysis.

Discussion
==========

In this study, we have investigated the prognostic significance of KRAS codons 12 and 13, and BRAF mutations in incident colorectal cancer from a large prospective cohort study, with particular reference to sex-related differences. As regards to the KRAS mutation status, the results demonstrated a significant association of KRAS codon 13 mutation, but not codon 12, with poor prognosis, but this significance was not retained in adjusted analysis. These results support precious findings by Bazan et al. who reported KRAS codon 13 mutation to be an independent predictor of a poor prognosis \[[@B5]\]. Samowitz et al. have also described similar associations, but only borderline significant \[[@B13]\]. Other studies have further reported any KRAS mutation to be associated with poor outcome \[[@B6]-[@B8],[@B32]\]. In the present study, subgroup analysis revealed that KRAS codon 13 mutation was only prognostic in women and not in men, but only in unadjusted analysis. While no significant associations were found between KRAS mutations and sex, the significant association of KRAS mutation with MSS tumours found here is in concordance with the results from previous studies \[[@B6],[@B7],[@B9]\]. Further, the associations of KRAS codon 13 mutation with metastatic disease and codon 12 mutation with mucinous tumour type have also been demonstrated previously \[[@B5]\]. Taken together, these findings further indicate that specific KRAS codon mutations have different impact on protein functionality and should be taken into consideration when evaluating KRAS mutation status in the clinical setting. Furthermore, in light of the accentuated prognostic impact of KRAS codon 13 mutation in women, it will also be of interest to perform further studies on the associations of hormonal factors with KRAS mutation status in CRC.

In analysis of the entire cohort, BRAF mutation was not prognostic in women, but in men; BRAF mutation was significantly associated with an impaired survival in adjusted, but not in unadjusted analysis. This may be explained by the fact that the prognostic impact of BRAF mutation status was stronger in, e.g. lymph node-positive disease in men, but not in women. It is well established that BRAF mutation, in contrast to KRAS mutation, is associated with MSI \[[@B9],[@B10],[@B16],[@B33]\] and female sex \[[@B10],[@B33],[@B34]\], and our findings further validate this. In MSS tumours, BRAF mutation was significantly associated with a reduced CSS in unadjusted analysis, and was borderline significant in adjusted analysis. These findings are in concordance with several previous studies \[[@B9],[@B15],[@B17],[@B35]\], indicating that BRAF-mutated/MSS tumours represent a more aggressive tumour phenotype. However, the results from this study further demonstrate that BRAF-mutated/MSS tumours were not significantly associated with poor prognosis in women, but an independent predictor of a reduced CSS in men.

To date, no biomarkers have yet been incorporated into clinical protocols for prognostication and treatment stratification of CRC patients in the adjuvant setting, which still relies entirely on the assessment of conventional clinicopathological factors and patient performance. Approximately 20% of patients with stage II disease will develop recurrent disease and although several risk factors, e.g. \<12 examined lymph nodes, T4 disease, vascular or neural invasion, low differentiation, acute operation and tumour perforation, have been suggested, the benefit from adjuvant chemotherapy in this patient category is rather modest \[[@B36],[@B37]\]. Our results further indicate that this algorithm is not only in need of additional molecular biomarkers, but that sex should also be included as a variable.

The main purpose of this study was to analyse and compare the prognostic significance of KRAS and BRAF mutations in women and men, irrespective of adjuvant treatment. However, potential differences in response to standard adjuvant chemotherapy in curatively treated patients with stages III and IV disease according to KRAS and BRAF mutational status, MSI status and sex were also examined, whereby no significant differences were found. Therefore, the finding of BRAF mutation being a particularly negative prognostic factor in men warrants validation in additional independent patient cohorts, which may well be done in the retrospective setting, before further prospective study.

Although the proportion of patients in this study that may have received EGFR inhibitors upon recurrent disease is likely to be negligible, it is also important to consider potential sex differences when evaluating the results from trials related to response to EGFR inhibitors. For instance, results from several trials have demonstrated a significantly better response to EGFR tyrosine kinase inhibitors in women with advanced non-small cell lung cancer compared to men \[[@B38],[@B39]\].

The higher prevalence of BRAF-mutated tumours in women, together with the lack of prognostic impact of BRAF mutations in female CRC, indicates the possibility of a link between hormonal factors and BRAF mutation status in CRC. Therefore, an influence of anthropometric and lifestyle factors is also plausible \[[@B22]\] and should be pursued in future studies.

As a cautionary remark, several of the here presented results, in particular related to gender, are derived from analyses of rather small subgroups and need validation in additional patient cohorts. The validity of the findings are however strengthened by the expected associations of KRAS and BRAF mutations with clinicopathological factors, e.g. KRAS and BRAF mutations being mutually exclusive \[[@B20]\], the significant associations between BRAF mutation, MSI \[[@B15],[@B20],[@B40]\] and mucinous phenotype \[[@B41],[@B42]\].

Apart from established clinicopathological parameters, we have also examined associations of KRAS and BRAF mutation status with several other investigative factors, i.e. beta-catenin overexpression and expression of p53, p21, p27 and cyclin D1. The observed inverse association between BRAF mutation and beta-catenin overexpression has been described earlier \[[@B43],[@B44]\] and is also in line with the previous findings of beta-catenin overexpression being associated with good prognosis in this cohort \[[@B28]\]. The observed associations between BRAF mutation and expression of p21 and cyclin D1, and loss of p27 and p53 expression have also been previously reported \[[@B45]-[@B48]\].

The Malmö Diet and Cancer Study is a population-based cohort study, wherein a potential selection bias compared with the general population must be taken into consideration. As previously denoted \[[@B23]\], the frequency of emergency surgery was only 8.3% which is lower than the commonly reported frequency of approximately 25% \[[@B49],[@B50]\], which may reflect a higher awareness of CRC among study participants. On the other hand, the distribution of clinical stages at diagnosis is in line with the expected \[[@B23],[@B25]\].

Conclusions
===========

In conclusion, the results from this large prospective cohort study provide further support to the accumulating evidence of BRAF-mutated microsatellite stable colorectal cancer having a particularly impaired prognosis. The finding of BRAF mutation being an independent factor of poor prognosis in male, but not in female colorectal cancer, both overall and in MSS tumours, is however novel and merits further study. Moreover, the findings in this study further emphasize the importance of taking sex into consideration in all cancer biomarker studies, since this may enable the development of more accurate prognostic nomograms for identification of patients with high-risk disease.
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